即刻乳房再造术后抗生素预防:其疗效的现实
基于Truven MarketScan数据库,纳入2010年1月至2014年6月间接受即刻假体乳房再造且有至少6个月随访的7443例患者,其中6049例(81%)术后使用抗生素预防。多变量回归显示,术后抗生素预防与感染相关取出、创口并发症、感染或感染再入院风险均无显著关联,且不同预防时长间感染相关结局无显著差异。
要点
- 7443例即刻假体乳房再造患者中,6049例(81%)术后使用抗生素预防。
- 术后抗生素预防与感染相关取出风险无显著关联(OR 0.82,95%CI 0.57–1.18)。
- 术后抗生素预防与创口并发症、感染、感染再入院风险均无显著关联。
核心结论
- 术后抗生素预防与假体乳房再造后感染或取出风险降低无关。
- 鉴于抗生素耐药率上升,作者认为关注技术因素和合并症管理可能更有效提升乳房再造安全性。
研究设计与样本
- 使用Truven MarketScan数据库的回顾性队列研究,纳入2010年1月至2014年6月间接受即刻假体乳房再造且有至少6个月随访的患者,共7443例。
主要发现
- 6049例(81%)患者术后使用抗生素预防。
- 术后抗生素预防组与非预防组相比,创口并发症风险无显著差异(OR 0.93,95%CI 0.71–1.23)。
- 术后抗生素预防组与非预防组相比,感染风险无显著差异(OR 0.89,95%CI 0.70–1.14)。
- 术后抗生素预防组与非预防组相比,感染相关取出风险无显著差异(OR 0.82,95%CI 0.57–1.18)。
- 术后抗生素预防组与非预防组相比,感染再入院风险无显著差异(OR 1.21,95%CI 0.82–1.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous techniques are used to prevent infection after immediate implant-based breast reconstruction. Postoperative antibiotic prophylaxis is commonly prescribed to decrease the risk of reconstructive failure, despite conflicting evidence regarding its effectiveness. The authors studied whether postoperative antibiotic prophylaxis decreases the risk of infection-related explantation in the setting of immediate prosthesis-based breast reconstruction. METHODS: Using Truven MarketScan databases, the authors identified all patients who underwent immediate implant reconstruction between January of 2010 and June of 2014 with at least 6 months of follow-up. Postoperative antibiotic prophylaxis was defined as any oral antibiotic course to be taken postoperatively based on prescriptions filled within 14 days preoperatively through 24 hours after discharge. Reconstructive failure, defined as explantation because of infection, was the primary outcome. Secondary outcomes of interest included wound complications, infection, and readmission for infection. Multivariable regression analyses controlled for demographic variables/comorbidities. RESULTS: Of the 7443 patients, 6049 (81 percent) filled prescriptions for postoperative antibiotic prophylaxis. These patients were equally likely to develop a wound complication (OR, 0.93; 95 percent CI, 0.71 to 1.23) or infection (OR, 0.89; 95 percent CI, 0.70 to 1.14), undergo explantation because of infection (OR, 0.82; 95 percent CI, 0.57 to 1.18), or require readmission for infection (OR, 1.21; 95 percent CI, 0.82 to 1.78) compared with those who did not receive antibiotics. There was no significant difference in the risk of infection-related outcomes based on postoperative antibiotic prophylaxis duration. CONCLUSIONS: Postoperative antibiotic prophylaxis was not associated with a reduced risk of infection or explantation following prosthesis-based breast reconstruction. Given rising rates of antibiotic resistance, focusing instead on technical considerations and the management of comorbid conditions may more effectively enhance the safety of breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Ranganathan K, Sears ED, Zhong L, et al. Antibiotic Prophylaxis after Immediate Breast Reconstruction: The Reality of Its Efficacy. Plast Reconstr Surg. 2018. PMID: 29240638. doi:10.1097/PRS.0000000000004204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。